A long-lasting universal flu vaccine
For decades, researchers have been doggedly pursuing a universal flu vaccine--one that would protect against the evolving influenza virus for years rather than just a single season--with little success. The bug mutates so quickly that a new vaccine must be specially formulated each year. But a relatively new strategy, targeting a rarely seen portion of the virus, is now showing some success.
A novel vaccine developed by microbiologist Peter Palese and collaborators at Mount Sinai School of Medicine in New York showed protective effects in rodents against three different flu strains, with protection ranging from mild (against hemagglutinin 1, such as that of the H1N1 or "swine" flu) to middling (against the avian flu H5 subtype) to absolute (against the common H3 flu subtype). While the results are far from perfect, the proof-of-principle demonstrates the potential for a universal flu vaccine.
- Readmissions: No Quick Fix to Costly Hospital Challenge
- Ebola: Health Officials Try to Quell Front Line Fears
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- Defensive Medicine Still Prevalent Despite Tort Reform
- How Top-Ranked MA Plans Earn Their Stars
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening
- Reducing Readmissions Starts with Better Collaboration
- Partners HealthCare M&A Deal Under Scrutiny
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients